Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge
In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three l...
Saved in:
Published in | Neuropharmacology Vol. 58; no. 3; pp. 632 - 639 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.03.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 μM or 300 μM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists. |
---|---|
AbstractList | In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 microM or 300 microM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists. In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 μM or 300 μM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists. In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 kM or 300 kM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists. In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 microM or 300 microM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists.In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain. We then examined the ability of the group II mGlu receptor agonist LY379268 to modulate the ketamine evoked increases in HA release in three limbic brain regions. Ketamine (25 mg/kg) increased HA in the medial prefrontal cortex (mPFC), ventral hippocampus (vHipp) and the nucleus accumbens (NAc) shell. LY379268 administered alone was without effect on basal HA efflux in the mPFC or vHipp but modestly decreased HA efflux in the NAc shell. Administration of LY379268 (3 and 10 mg/kg) prior to ketamine significantly attenuated the HA response in the mPFC, vHipp and the NAc shell. The inhibitory effects of LY379268 in the mPFC were mimicked by the systemic administration of the mGlu2 receptor positive allosteric modulator CBiPES (60 mg/kg). Finally, local perfusion experiments revealed that the effects of LY379268 on ketamine evoked HA efflux appear to be mediated by mGlu2 receptors outside the PFC as the intra-mPFC perfusion of LY379268 (100 microM or 300 microM) failed to attenuate ketamine evoked increases in HA efflux. Together, these novel observations reveal an effect of ketamine on histaminergic transmission in limbic brain areas and provide further insight into the possible antipsychotic mechanism of action of mGlu2/3 receptor agonists. |
Author | Schkeryantz, Jeffrey M. Khilevich, Albert Perry, Kenneth W. Katner, Jason S. Fell, Matthew J. Johnson, Bryan G. Svensson, Kjell A. |
Author_xml | – sequence: 1 givenname: Matthew J. surname: Fell fullname: Fell, Matthew J. email: Fell_matthew@lilly.com – sequence: 2 givenname: Jason S. surname: Katner fullname: Katner, Jason S. – sequence: 3 givenname: Bryan G. surname: Johnson fullname: Johnson, Bryan G. – sequence: 4 givenname: Albert surname: Khilevich fullname: Khilevich, Albert – sequence: 5 givenname: Jeffrey M. surname: Schkeryantz fullname: Schkeryantz, Jeffrey M. – sequence: 6 givenname: Kenneth W. surname: Perry fullname: Perry, Kenneth W. – sequence: 7 givenname: Kjell A. surname: Svensson fullname: Svensson, Kjell A. |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19951716$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc1u1DAURi1URKeFV0Be8bNI8E0cJ9kglQpapEpsYG05npsZD44dbKcVL8Ez4-kMVGJBV5blc4-vvu-MnDjvkBAKrAQG4t2udLgEP29VmMqKsb4EKBnwJ2QFXVsXLRP8hKwYq7qi7ll3Ss5i3DHGeAfdM3IKfd9AC2JFfl3oZG5VMt5RP9IJkxp8ymqj6cYuSU0qIX0zXdnlbUUDapyTD5HGZZ4DxoiRbk3MmHGYny2qiNQ4as00ZMUQVL4E3GR_pKO31t8Zt6FKL1n7HY-DequsRbfB5-TpqGzEF8fznHz79PHr5XVx8-Xq8-XFTaF5y1KBVc9F3QjW1tA13SBY3ba6qUCP48i1ELyqkQ9C8aHPHAPW6IEP7agRKgG8PievD945-B8LxiQnEzVaqxz6Jcq2rrO3Acjkq_-SFVR9B_Ve-fIILsOEazkHM6nwU_7JOgPvD4AOPsaAo9Qm3SefckpWApP7cuVOPpQr9-VKAMnul-7-Efz94_HRD4dRzKHeGgwyaoNO49rkTpNce_O45DchhMfH |
CitedBy_id | crossref_primary_10_1016_j_jemermed_2016_09_020 crossref_primary_10_1177_2045125311400779 crossref_primary_10_1016_j_eplepsyres_2013_10_009 crossref_primary_10_1016_j_neuroscience_2013_07_010 crossref_primary_10_1021_cn200008d crossref_primary_10_1016_j_neuroscience_2011_07_034 crossref_primary_10_1371_journal_pone_0144017 crossref_primary_10_1152_jn_00462_2021 crossref_primary_10_1007_s13760_014_0407_7 crossref_primary_10_1038_npp_2013_290 crossref_primary_10_1016_j_neuroscience_2010_12_012 crossref_primary_10_3389_fnmol_2018_00383 crossref_primary_10_1016_j_neuropharm_2020_108072 crossref_primary_10_1038_nbt_2914 crossref_primary_10_1007_s11172_013_0123_0 crossref_primary_10_1016_j_neulet_2011_03_050 crossref_primary_10_1038_tp_2017_198 crossref_primary_10_1254_jphs_10022FP crossref_primary_10_1016_j_neuropharm_2015_05_034 crossref_primary_10_1124_pr_119_019133 crossref_primary_10_1016_j_neuropharm_2011_06_007 crossref_primary_10_1124_jpet_110_172957 crossref_primary_10_1016_j_pbb_2017_05_004 crossref_primary_10_1007_s00702_020_02287_8 |
Cites_doi | 10.1016/0920-9964(94)00034-6 10.1002/(SICI)1096-9861(20000403)419:2<205::AID-CNE5>3.0.CO;2-0 10.1016/j.neuropharm.2008.06.016 10.1124/jpet.108.136861 10.1523/JNEUROSCI.17-08-02921.1997 10.1016/0006-8993(87)90802-X 10.1016/0028-3908(90)90034-O 10.1038/sj.bjp.0702994 10.1016/S0014-2999(00)00269-7 10.1038/sj.npp.1300238 10.1016/0091-3057(94)90506-1 10.1002/cne.903110105 10.1038/nm1632 10.1016/j.euroneuro.2004.10.001 10.1016/S0006-8993(97)00255-2 10.1016/S0306-4522(02)00652-8 10.1093/bja/83.6.945 10.1046/j.1471-4159.1996.67010171.x 10.2174/1568007024606177 10.1007/s00213-007-0974-x 10.1002/syn.10043 10.1196/annals.1300.019 10.1126/science.281.5381.1349 10.1016/0006-3223(91)90290-3 10.1046/j.1460-9568.1999.00519.x 10.1016/S0014-2999(97)01435-0 10.1016/j.bcp.2004.07.034 10.1016/0028-3908(88)90189-X 10.1152/physrev.1991.71.1.1 10.1016/S0301-0082(00)00039-3 10.1016/S0006-8993(97)00932-3 10.1523/JNEUROSCI.18-12-04705.1998 10.1111/j.1460-9568.2005.04450.x 10.1111/j.1471-4159.2006.04002.x 10.1176/ajp.148.10.1301 |
ContentType | Journal Article |
Copyright | 2009 Elsevier Ltd Copyright 2009 Elsevier Ltd. All rights reserved. Copyright 2009 Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2009 Elsevier Ltd – notice: Copyright 2009 Elsevier Ltd. All rights reserved. – notice: Copyright 2009 Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK 7X8 |
DOI | 10.1016/j.neuropharm.2009.11.014 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Neurosciences Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-7064 |
EndPage | 639 |
ExternalDocumentID | 19951716 10_1016_j_neuropharm_2009_11_014 S0028390809003621 |
Genre | Journal Article |
GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29N 3O- 4.4 41~ 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATCM AAXLA AAXUO ABCQJ ABFNM ABFRF ABIVO ABJNI ABMAC ABXDB ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADIYS ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AQVPL ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMQ HMT HVGLF HZ~ IHE J1W K-O KOM L7B M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SES SEW SNS SPCBC SPT SSN SSP SSZ T5K TEORI WUQ X7M XOL ZGI ZXP ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKYEP ANKPU APXCP BNPGV CITATION SSH CGR CUY CVF ECM EIF NPM PKN 7TK EFKBS 7X8 |
ID | FETCH-LOGICAL-c470t-e29463560731858b60377c521cfff4c66423e4b6a4b96350105cb4b7fce126143 |
IEDL.DBID | .~1 |
ISSN | 0028-3908 1873-7064 |
IngestDate | Thu Jul 10 23:58:24 EDT 2025 Sun Aug 24 04:11:12 EDT 2025 Wed Feb 19 01:49:00 EST 2025 Tue Jul 01 01:51:23 EDT 2025 Thu Apr 24 23:09:25 EDT 2025 Tue Apr 02 10:07:20 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | LY379268 mGlu2/3 receptors Histamine Ketamine CBiPES In vivo microdialysis |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright 2009 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c470t-e29463560731858b60377c521cfff4c66423e4b6a4b96350105cb4b7fce126143 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 19951716 |
PQID | 21298134 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_733858511 proquest_miscellaneous_21298134 pubmed_primary_19951716 crossref_citationtrail_10_1016_j_neuropharm_2009_11_014 crossref_primary_10_1016_j_neuropharm_2009_11_014 elsevier_sciencedirect_doi_10_1016_j_neuropharm_2009_11_014 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | March 2010 2010-03-00 2010-Mar 20100301 |
PublicationDateYYYYMMDD | 2010-03-01 |
PublicationDate_xml | – month: 03 year: 2010 text: March 2010 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Neuropharmacology |
PublicationTitleAlternate | Neuropharmacology |
PublicationYear | 2010 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Moghaddam, Adams (bib18) 1998; 281 Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press. Wouterlood, Steinbusch, Luiten, Bol (bib35) 1987; 406 Fell, Johnson, Svensson, Schoepp (bib8) 2008; 326 Lorrain, Baccei, Bristow, Anderson, Varney (bib15) 2003; 117 Kishi, Tsumori, Ono, Yokota, Ishino, Yasui (bib12) 2000; 419 Faucard, Armand, Heron, Cochois, Schwartz, Arrang (bib7) 2006; 98 Patil, Zhang, Martenyi, Lowe, Jackson, Andreev, Avedisova, Bardenstein, Gurovich, Morozova, Mosolov, Neznanov, Reznik, Smulevich, Tochilov, Johnson, Monn, Schoepp (bib23) 2007; 13 Prell, Green, Kaufmann, Khandelwal, Morrishow, Kirch, Linnoila, Wyatt (bib25) 1995; 14 Moghaddam, Adams, Verma, Daly (bib17) 1997; 17 Spooren, Gasparini, van der Putten, Koller, Nakanishi, Kuhn (bib30) 2000; 397 Yang, Hatton (bib36) 1997; 773 Iwabuchi, Ito, Tashiro, Kato, Kano, Itoh, Iwata, Matsuoka, Sato, Yanai (bib10) 2005; 15 Javitt, Zukin (bib11) 1991; 148 Lindefors, Barati, O'Connor (bib14) 1997; 759 Parada-Turska, Turski (bib22) 1990; 29 Stevens, Kuramasu, Haas (bib31) 1999; 11 Swanson, Schoepp (bib32) 2003; 1003 Itoh, Oishi, Nishibori, Saeki (bib9) 1985; 235 Perry, Falcone, Fell, Ryder, Yu, Love, Katner, Gordon, Wade, Man, Nomikos, Phebus, Cauvin, Johnson, Jones, Hoffmann, Sandusky, Walter, Porter, Yang, Merchant, Shannon, Svensson (bib24) 2008; 55 Okakura-Mochizuki, Mochizuki, Yamamoto, Horii, Yamatodani (bib20) 1996; 67 Brown, Stevens, Haas (bib2) 2001; 63 Danysz, Wroblewski, Costa (bib5) 1988; 27 Ericson, Blomqvist, Kohler (bib6) 1991; 311 Kubota, Hirota, Yoshida, Takahashi, Ohkawa, Anzawa, Kushikata, Matsuki (bib13) 1999; 83 Schoepp (bib26) 2001; 299 Schoepp, Marek (bib27) 2002; 1 Danysz, Essmann, Bresink, Wilke (bib4) 1994; 48 Sherin, Elmquist, Torrealba, Saper (bib29) 1998; 18 Yonezawa, Kuroki, Kawahara, Tashiro, Uchimura (bib37) 1998; 341 Nakai, Kitamura, Hashimoto, Kajimoto, Nishino, Mita, Tanaka (bib19) 1991; 30 Westerink, Cremers, De Vries, Liefers, Tran, De Boer (bib33) 2002; 43 Lorrain, Schaffhauser, Campbell, Baccei, Correa, Rowe, Rodriguez, Anderson, Varney, Pinkerton, Vernier, Bristow (bib16) 2003; 28 Woolley, Pemberton, Bate, Corti, Jones (bib34) 2008; 196 Coyle (bib3) 2004; 68 Okamura, Yanai, Higuchi, Sakai, Iwata, Ido, Sasaki, Watanabe, Itoh (bib21) 2000; 129 Aggleton, Vann, Saunders (bib1) 2005; 22 Schwartz, Arrang, Garbarg, Pollard, Ruat (bib28) 1991; 71 Parada-Turska (10.1016/j.neuropharm.2009.11.014_bib22) 1990; 29 Yang (10.1016/j.neuropharm.2009.11.014_bib36) 1997; 773 Fell (10.1016/j.neuropharm.2009.11.014_bib8) 2008; 326 Prell (10.1016/j.neuropharm.2009.11.014_bib25) 1995; 14 Itoh (10.1016/j.neuropharm.2009.11.014_bib9) 1985; 235 Lindefors (10.1016/j.neuropharm.2009.11.014_bib14) 1997; 759 Schoepp (10.1016/j.neuropharm.2009.11.014_bib27) 2002; 1 Yonezawa (10.1016/j.neuropharm.2009.11.014_bib37) 1998; 341 Okamura (10.1016/j.neuropharm.2009.11.014_bib21) 2000; 129 Patil (10.1016/j.neuropharm.2009.11.014_bib23) 2007; 13 Kishi (10.1016/j.neuropharm.2009.11.014_bib12) 2000; 419 Kubota (10.1016/j.neuropharm.2009.11.014_bib13) 1999; 83 Aggleton (10.1016/j.neuropharm.2009.11.014_bib1) 2005; 22 Lorrain (10.1016/j.neuropharm.2009.11.014_bib15) 2003; 117 Sherin (10.1016/j.neuropharm.2009.11.014_bib29) 1998; 18 Westerink (10.1016/j.neuropharm.2009.11.014_bib33) 2002; 43 Ericson (10.1016/j.neuropharm.2009.11.014_bib6) 1991; 311 Okakura-Mochizuki (10.1016/j.neuropharm.2009.11.014_bib20) 1996; 67 Danysz (10.1016/j.neuropharm.2009.11.014_bib5) 1988; 27 Moghaddam (10.1016/j.neuropharm.2009.11.014_bib18) 1998; 281 Nakai (10.1016/j.neuropharm.2009.11.014_bib19) 1991; 30 Faucard (10.1016/j.neuropharm.2009.11.014_bib7) 2006; 98 Schoepp (10.1016/j.neuropharm.2009.11.014_bib26) 2001; 299 Schwartz (10.1016/j.neuropharm.2009.11.014_bib28) 1991; 71 Javitt (10.1016/j.neuropharm.2009.11.014_bib11) 1991; 148 Perry (10.1016/j.neuropharm.2009.11.014_bib24) 2008; 55 Danysz (10.1016/j.neuropharm.2009.11.014_bib4) 1994; 48 10.1016/j.neuropharm.2009.11.014_bib38 Woolley (10.1016/j.neuropharm.2009.11.014_bib34) 2008; 196 Wouterlood (10.1016/j.neuropharm.2009.11.014_bib35) 1987; 406 Iwabuchi (10.1016/j.neuropharm.2009.11.014_bib10) 2005; 15 Swanson (10.1016/j.neuropharm.2009.11.014_bib32) 2003; 1003 Brown (10.1016/j.neuropharm.2009.11.014_bib2) 2001; 63 Spooren (10.1016/j.neuropharm.2009.11.014_bib30) 2000; 397 Stevens (10.1016/j.neuropharm.2009.11.014_bib31) 1999; 11 Lorrain (10.1016/j.neuropharm.2009.11.014_bib16) 2003; 28 Coyle (10.1016/j.neuropharm.2009.11.014_bib3) 2004; 68 Moghaddam (10.1016/j.neuropharm.2009.11.014_bib17) 1997; 17 |
References_xml | – volume: 326 start-page: 209 year: 2008 end-page: 231 ident: bib8 article-title: Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039 publication-title: J. Pharmacol. Exp. Ther. – volume: 30 start-page: 349 year: 1991 end-page: 356 ident: bib19 article-title: Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia publication-title: Biol. Psychiatry – reference: Paxinos, G., Watson, C., 1986. The Rat Brain in Stereotaxic Coordinates. San Diego, Academic Press. – volume: 235 start-page: 788 year: 1985 end-page: 792 ident: bib9 article-title: Phencyclidine and the dynamics of mouse brain histamine publication-title: J. Pharmacol. Exp. Ther. – volume: 67 start-page: 171 year: 1996 end-page: 176 ident: bib20 article-title: Endogenous GABA modulates histamine release from the anterior hypothalamus of the rat publication-title: J. Neurochem. – volume: 1003 start-page: 309 year: 2003 end-page: 317 ident: bib32 article-title: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists publication-title: Ann. N. Y. Acad. Sci. – volume: 27 start-page: 653 year: 1988 end-page: 656 ident: bib5 article-title: Learning impairment in rats by N-methyl-D-aspartate receptor antagonists publication-title: Neuropharmacology – volume: 117 start-page: 697 year: 2003 end-page: 706 ident: bib15 article-title: Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 publication-title: Neuroscience – volume: 196 start-page: 431 year: 2008 end-page: 440 ident: bib34 article-title: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity publication-title: Psychopharmacology (Berl) – volume: 148 start-page: 1301 year: 1991 end-page: 1308 ident: bib11 article-title: Recent advances in the phencyclidine model of schizophrenia publication-title: Am. J. Psychiatry – volume: 28 start-page: 1622 year: 2003 end-page: 1632 ident: bib16 article-title: Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge publication-title: Neuropsychopharmacology – volume: 13 start-page: 1102 year: 2007 end-page: 1107 ident: bib23 article-title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial publication-title: Nat. Med. – volume: 48 start-page: 111 year: 1994 end-page: 118 ident: bib4 article-title: Glutamate antagonists have different effects on spontaneous locomotor activity in rats publication-title: Pharmacol. Biochem. Behav. – volume: 18 start-page: 4705 year: 1998 end-page: 4721 ident: bib29 article-title: Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat publication-title: J. Neurosci. – volume: 406 start-page: 330 year: 1987 end-page: 336 ident: bib35 article-title: Projection from the prefrontal cortex to histaminergic cell groups in the posterior hypothalamic region of the rat. Anterograde tracing with publication-title: Brain Res. – volume: 98 start-page: 1487 year: 2006 end-page: 1496 ident: bib7 article-title: N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain publication-title: J. Neurochem. – volume: 17 start-page: 2921 year: 1997 end-page: 2927 ident: bib17 article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to sopaminergic and cognitive disruptions associated with the prefrontal cortex publication-title: J. Neurosci. – volume: 14 start-page: 93 year: 1995 end-page: 104 ident: bib25 article-title: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms publication-title: Schizophr. Res. – volume: 63 start-page: 637 year: 2001 end-page: 672 ident: bib2 article-title: The physiology of brain histamine publication-title: Prog. Neurobiol. – volume: 129 start-page: 115 year: 2000 end-page: 123 ident: bib21 article-title: Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine publication-title: Br. J. Pharmacol. – volume: 311 start-page: 45 year: 1991 end-page: 64 ident: bib6 article-title: Origin of neuronal inputs to the region of the tuberomammillary nucleus of the rat brain publication-title: J. Comp. Neurol. – volume: 759 start-page: 205 year: 1997 end-page: 212 ident: bib14 article-title: Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex publication-title: Brain Res. – volume: 68 start-page: 1507 year: 2004 end-page: 1514 ident: bib3 article-title: The GABA-glutamate connection in schizophrenia: which is the proximate cause? publication-title: Biochem. Pharmacol. – volume: 397 start-page: R1 year: 2000 ident: bib30 article-title: Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice publication-title: Eur. J. Pharmacol. – volume: 43 start-page: 238 year: 2002 end-page: 243 ident: bib33 article-title: Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat publication-title: Synapse – volume: 341 start-page: 45 year: 1998 end-page: 56 ident: bib37 article-title: Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex publication-title: Eur. J. Pharmacol. – volume: 22 start-page: 2519 year: 2005 end-page: 2530 ident: bib1 article-title: Projections from the hippocampal region to the mammillary bodies in macaque monkeys publication-title: Eur. J. Neurosci. – volume: 773 start-page: 162 year: 1997 end-page: 172 ident: bib36 article-title: Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites publication-title: Brain Res. – volume: 55 start-page: 743 year: 2008 end-page: 754 ident: bib24 article-title: Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas publication-title: Neuropharmacology – volume: 419 start-page: 205 year: 2000 end-page: 222 ident: bib12 article-title: Topographical organization of projections from the subiculum to the hypothalamus in the rat publication-title: J. Comp. Neurol. – volume: 299 start-page: 12 year: 2001 end-page: 20 ident: bib26 article-title: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system publication-title: J. Pharmacol. Exp. Ther. – volume: 83 start-page: 945 year: 1999 end-page: 947 ident: bib13 article-title: Inhibitory effect of clonidine on ketamine-induced norepinephrine release from the medial prefrontal cortex in rats publication-title: Br. J. Anaesth. – volume: 281 start-page: 1349 year: 1998 end-page: 1352 ident: bib18 article-title: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats publication-title: Science – volume: 29 start-page: 1111 year: 1990 end-page: 1116 ident: bib22 article-title: Excitatory amino acid antagonists and memory: effect of drugs acting at publication-title: Neuropharmacology – volume: 15 start-page: 185 year: 2005 end-page: 191 ident: bib10 article-title: Histamine H1 receptors in schizophrenic patients measured by positron emission tomography publication-title: Eur. Neuropsychopharmacol. – volume: 1 start-page: 215 year: 2002 end-page: 225 ident: bib27 article-title: Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? publication-title: Curr. Drug Targets CNS Neurol. Disord. – volume: 71 start-page: 1 year: 1991 end-page: 51 ident: bib28 article-title: Histaminergic transmission in the mammalian brain publication-title: Physiol. Rev. – volume: 11 start-page: 1148 year: 1999 end-page: 1154 ident: bib31 article-title: GABAB-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro publication-title: Eur. J. Neurosci. – volume: 14 start-page: 93 year: 1995 ident: 10.1016/j.neuropharm.2009.11.014_bib25 article-title: Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationships to levels of other aminergic transmitters and ratings of symptoms publication-title: Schizophr. Res. doi: 10.1016/0920-9964(94)00034-6 – volume: 419 start-page: 205 year: 2000 ident: 10.1016/j.neuropharm.2009.11.014_bib12 article-title: Topographical organization of projections from the subiculum to the hypothalamus in the rat publication-title: J. Comp. Neurol. doi: 10.1002/(SICI)1096-9861(20000403)419:2<205::AID-CNE5>3.0.CO;2-0 – volume: 55 start-page: 743 year: 2008 ident: 10.1016/j.neuropharm.2009.11.014_bib24 article-title: Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas publication-title: Neuropharmacology doi: 10.1016/j.neuropharm.2008.06.016 – volume: 326 start-page: 209 year: 2008 ident: 10.1016/j.neuropharm.2009.11.014_bib8 article-title: Evidence for the role of mGlu2 not mGlu3 receptors in the pre-clinical antipsychotic pharmacology of the mGlu2/3 receptor agonist LY404039 publication-title: J. Pharmacol. Exp. Ther. doi: 10.1124/jpet.108.136861 – volume: 17 start-page: 2921 year: 1997 ident: 10.1016/j.neuropharm.2009.11.014_bib17 article-title: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to sopaminergic and cognitive disruptions associated with the prefrontal cortex publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.17-08-02921.1997 – volume: 406 start-page: 330 year: 1987 ident: 10.1016/j.neuropharm.2009.11.014_bib35 article-title: Projection from the prefrontal cortex to histaminergic cell groups in the posterior hypothalamic region of the rat. Anterograde tracing with Phaseolus vulgaris leucoagglutinin combined with immunocytochemistry of histidine decarboxylase publication-title: Brain Res. doi: 10.1016/0006-8993(87)90802-X – volume: 29 start-page: 1111 year: 1990 ident: 10.1016/j.neuropharm.2009.11.014_bib22 article-title: Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-d-aspartate receptors in learning and memory tasks publication-title: Neuropharmacology doi: 10.1016/0028-3908(90)90034-O – volume: 129 start-page: 115 year: 2000 ident: 10.1016/j.neuropharm.2009.11.014_bib21 article-title: Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine publication-title: Br. J. Pharmacol. doi: 10.1038/sj.bjp.0702994 – volume: 397 start-page: R1 year: 2000 ident: 10.1016/j.neuropharm.2009.11.014_bib30 article-title: Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(00)00269-7 – volume: 28 start-page: 1622 year: 2003 ident: 10.1016/j.neuropharm.2009.11.014_bib16 article-title: Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge publication-title: Neuropsychopharmacology doi: 10.1038/sj.npp.1300238 – volume: 48 start-page: 111 year: 1994 ident: 10.1016/j.neuropharm.2009.11.014_bib4 article-title: Glutamate antagonists have different effects on spontaneous locomotor activity in rats publication-title: Pharmacol. Biochem. Behav. doi: 10.1016/0091-3057(94)90506-1 – volume: 311 start-page: 45 year: 1991 ident: 10.1016/j.neuropharm.2009.11.014_bib6 article-title: Origin of neuronal inputs to the region of the tuberomammillary nucleus of the rat brain publication-title: J. Comp. Neurol. doi: 10.1002/cne.903110105 – volume: 13 start-page: 1102 year: 2007 ident: 10.1016/j.neuropharm.2009.11.014_bib23 article-title: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial publication-title: Nat. Med. doi: 10.1038/nm1632 – volume: 15 start-page: 185 year: 2005 ident: 10.1016/j.neuropharm.2009.11.014_bib10 article-title: Histamine H1 receptors in schizophrenic patients measured by positron emission tomography publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2004.10.001 – volume: 759 start-page: 205 year: 1997 ident: 10.1016/j.neuropharm.2009.11.014_bib14 article-title: Differential effects of single and repeated ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal cortex publication-title: Brain Res. doi: 10.1016/S0006-8993(97)00255-2 – volume: 117 start-page: 697 year: 2003 ident: 10.1016/j.neuropharm.2009.11.014_bib15 article-title: Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 publication-title: Neuroscience doi: 10.1016/S0306-4522(02)00652-8 – volume: 83 start-page: 945 year: 1999 ident: 10.1016/j.neuropharm.2009.11.014_bib13 article-title: Inhibitory effect of clonidine on ketamine-induced norepinephrine release from the medial prefrontal cortex in rats publication-title: Br. J. Anaesth. doi: 10.1093/bja/83.6.945 – volume: 67 start-page: 171 year: 1996 ident: 10.1016/j.neuropharm.2009.11.014_bib20 article-title: Endogenous GABA modulates histamine release from the anterior hypothalamus of the rat publication-title: J. Neurochem. doi: 10.1046/j.1471-4159.1996.67010171.x – volume: 1 start-page: 215 year: 2002 ident: 10.1016/j.neuropharm.2009.11.014_bib27 article-title: Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? publication-title: Curr. Drug Targets CNS Neurol. Disord. doi: 10.2174/1568007024606177 – volume: 196 start-page: 431 year: 2008 ident: 10.1016/j.neuropharm.2009.11.014_bib34 article-title: The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity publication-title: Psychopharmacology (Berl) doi: 10.1007/s00213-007-0974-x – volume: 43 start-page: 238 year: 2002 ident: 10.1016/j.neuropharm.2009.11.014_bib33 article-title: Evidence for activation of histamine H3 autoreceptors during handling stress in the prefrontal cortex of the rat publication-title: Synapse doi: 10.1002/syn.10043 – volume: 1003 start-page: 309 year: 2003 ident: 10.1016/j.neuropharm.2009.11.014_bib32 article-title: A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists publication-title: Ann. N. Y. Acad. Sci. doi: 10.1196/annals.1300.019 – volume: 281 start-page: 1349 year: 1998 ident: 10.1016/j.neuropharm.2009.11.014_bib18 article-title: Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats publication-title: Science doi: 10.1126/science.281.5381.1349 – volume: 30 start-page: 349 year: 1991 ident: 10.1016/j.neuropharm.2009.11.014_bib19 article-title: Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia publication-title: Biol. Psychiatry doi: 10.1016/0006-3223(91)90290-3 – volume: 11 start-page: 1148 year: 1999 ident: 10.1016/j.neuropharm.2009.11.014_bib31 article-title: GABAB-receptor-mediated control of GABAergic inhibition in rat histaminergic neurons in vitro publication-title: Eur. J. Neurosci. doi: 10.1046/j.1460-9568.1999.00519.x – volume: 299 start-page: 12 year: 2001 ident: 10.1016/j.neuropharm.2009.11.014_bib26 article-title: Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system publication-title: J. Pharmacol. Exp. Ther. – ident: 10.1016/j.neuropharm.2009.11.014_bib38 – volume: 341 start-page: 45 year: 1998 ident: 10.1016/j.neuropharm.2009.11.014_bib37 article-title: Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex publication-title: Eur. J. Pharmacol. doi: 10.1016/S0014-2999(97)01435-0 – volume: 235 start-page: 788 year: 1985 ident: 10.1016/j.neuropharm.2009.11.014_bib9 article-title: Phencyclidine and the dynamics of mouse brain histamine publication-title: J. Pharmacol. Exp. Ther. – volume: 68 start-page: 1507 year: 2004 ident: 10.1016/j.neuropharm.2009.11.014_bib3 article-title: The GABA-glutamate connection in schizophrenia: which is the proximate cause? publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2004.07.034 – volume: 27 start-page: 653 year: 1988 ident: 10.1016/j.neuropharm.2009.11.014_bib5 article-title: Learning impairment in rats by N-methyl-D-aspartate receptor antagonists publication-title: Neuropharmacology doi: 10.1016/0028-3908(88)90189-X – volume: 71 start-page: 1 year: 1991 ident: 10.1016/j.neuropharm.2009.11.014_bib28 article-title: Histaminergic transmission in the mammalian brain publication-title: Physiol. Rev. doi: 10.1152/physrev.1991.71.1.1 – volume: 63 start-page: 637 year: 2001 ident: 10.1016/j.neuropharm.2009.11.014_bib2 article-title: The physiology of brain histamine publication-title: Prog. Neurobiol. doi: 10.1016/S0301-0082(00)00039-3 – volume: 773 start-page: 162 year: 1997 ident: 10.1016/j.neuropharm.2009.11.014_bib36 article-title: Electrophysiology of excitatory and inhibitory afferents to rat histaminergic tuberomammillary nucleus neurons from hypothalamic and forebrain sites publication-title: Brain Res. doi: 10.1016/S0006-8993(97)00932-3 – volume: 18 start-page: 4705 year: 1998 ident: 10.1016/j.neuropharm.2009.11.014_bib29 article-title: Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.18-12-04705.1998 – volume: 22 start-page: 2519 year: 2005 ident: 10.1016/j.neuropharm.2009.11.014_bib1 article-title: Projections from the hippocampal region to the mammillary bodies in macaque monkeys publication-title: Eur. J. Neurosci. doi: 10.1111/j.1460-9568.2005.04450.x – volume: 98 start-page: 1487 year: 2006 ident: 10.1016/j.neuropharm.2009.11.014_bib7 article-title: N-methyl-D-aspartate receptor antagonists enhance histamine neuron activity in rodent brain publication-title: J. Neurochem. doi: 10.1111/j.1471-4159.2006.04002.x – volume: 148 start-page: 1301 year: 1991 ident: 10.1016/j.neuropharm.2009.11.014_bib11 article-title: Recent advances in the phencyclidine model of schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/ajp.148.10.1301 |
SSID | ssj0004818 |
Score | 2.0876653 |
Snippet | In the present study we demonstrated that ketamine, an NMDA antagonist and possible psychotomimetic, increases extracellular histamine (HA) in the rat brain.... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 632 |
SubjectTerms | Amino Acids - pharmacology Analysis of Variance Animals Bridged Bicyclo Compounds, Heterocyclic - pharmacology CBiPES Cyclopropanes - pharmacology Dose-Response Relationship, Drug Drug Interactions Electrochemistry - methods Excitatory Amino Acid Agonists - pharmacology Excitatory Amino Acid Antagonists - pharmacology Histamine Histamine - metabolism In vivo microdialysis Indoles - pharmacology Ketamine Ketamine - pharmacology Limbic System - anatomy & histology Limbic System - drug effects Limbic System - metabolism LY379268 Male mGlu2/3 receptors Microdialysis - methods Quinoxalines - pharmacology Rats Rats, Sprague-Dawley Receptors, Metabotropic Glutamate - agonists Receptors, Metabotropic Glutamate - antagonists & inhibitors Receptors, Metabotropic Glutamate - metabolism |
Title | Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge |
URI | https://dx.doi.org/10.1016/j.neuropharm.2009.11.014 https://www.ncbi.nlm.nih.gov/pubmed/19951716 https://www.proquest.com/docview/21298134 https://www.proquest.com/docview/733858511 |
Volume | 58 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELUQXLigQqHd8tE5IEQlApvEiR1xWqHShaqIA0jcothxqrS72YhNhPbCT-A3MxMnRD2shNRrZEdWPJ55Vt68x9ihJ1zPhEPppInQDpc8cGQQDYnTkAolNA8lNTj_ugnH9_z6IXhYYRddLwzRKtvcb3N6k63bJ2ft1zwr85x6fLE0Roh4okZUpelg54Ki_PS5p3lw6cpOiZlGt2wey_FqNCNL0oi2ypWk5-nyZSVqGQRtStHlB7bRYkgY2WVushVTbLGjWytCvTiBu76nan4CR3Dby1MvPrKXke4szWCWwdRUGAcVLjDX8BvjMEEMa-B4-mNSf_MAP44pyZEH5nXZkGbNHEikOJkiPgWyXME6CHkBk3yq8BWKPCeA_B4wniHDMJs9YXmERNf42r-mnag7E5dtdn_5_e5i7LSuDI7mYlg5xos4idphbsBaL1U49IXQiAJ0lmVch3ih8Q1XYcIVHu6AHDi14kpk2rh4XeP-DlstZoX5zECpANND6go_CXgaeSpFAEJ6-iqQiGv4gIluI2LdSpaTc8Yk7rhpf-J-C8lRM8IbTYxbOGDu28zSyna8Y855t9fxPyEYY3V5x-yvXXjEeELpt0tSmFk9jxEcRNL1cQQsGSF8-3vWHbBPNrD6RUcIgfFO--W_FrfL1i3rgbhze2y1eqzNPoKpSh00p-WArY2ufo5vXgGzQCHi |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9wwELUQHOBStaW02y_mUCGQSNkkTuyoJ4QKSwuIwyJxs2LHqdLuZqNuoooLP4HfzEycNOphJaReIzuy4vHMG-X5PcY-BcIPbDyWXpYK43HJI09GyZg4DZnQwvBY0gXny6t4csO_3Ua3a-ykvwtDtMou97uc3mbr7slR9zWPqqKgO75YGhNEPEkrqoIt0AbH40s2Bp_vB54Hl77spZhpeEfncSSvVjSyIpFoJ11Jgp4-X1WjVmHQthadPmfPOhAJx26dL9iaLV-yvWunQn13CNPhUtXyEPbgetCnvttmD8em9zSDRQ5zW2Mg1LjAwsAPDMQUQayF_fnZrDkIAL-OrciSB5ZN1bJm7RJIpTidI0AF8lzBQghFCbNirvEVmkwngAwfMKAhxzhb_MH6CKlp8LW_bDfR9C4ur9jN6dfpycTrbBk8w8W49myQcFK1w-SAxV7qeBwKYRAGmDzPuYmxowkt13HKNZ7uiCw4jeZa5Mb62K_xcIetl4vSvmGgdYT5IfNFmEY8SwKdIQIhQX0dSQQ2fMREvxHKdJrlZJ0xUz057acatpAsNRNsaRRu4Yj5f2dWTrfjCXO-9Hut_olBheXlCbN3-_BQeETpv0ta2kWzVIgOEumHOAJWjBCh-z_rj9hrF1jDohPEwNjUvv2vxe2yzcn08kJdnF99f8e2HAWCiHTv2Xr9u7EfEFnV-mN7ch4BFrEjcA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activation+of+metabotropic+glutamate+%28mGlu%292+receptors+suppresses+histamine+release+in+limbic+brain+regions+following+acute+ketamine+challenge&rft.jtitle=Neuropharmacology&rft.au=Fell%2C+Matthew+J&rft.au=Katner%2C+Jason+S&rft.au=Johnson%2C+Bryan+G&rft.au=Khilevich%2C+Albert&rft.date=2010-03-01&rft.issn=1873-7064&rft.eissn=1873-7064&rft.volume=58&rft.issue=3&rft.spage=632&rft_id=info:doi/10.1016%2Fj.neuropharm.2009.11.014&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-3908&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-3908&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-3908&client=summon |